Australia’s Brandon Capital leads AU$29 M series A investment in Glyscend’s diabetes polymer compound

July 21, 2020

PERTH, Australia – With a series A investment in hand, Glyscend Therapeutics Inc. will take its polymer therapeutic that mimics the effect of gastric bypass surgery to Australia next year to begin clinical trials.

BioWorld Asia Newco news Diabetes Series A

Today's news in brief

BioWorld

BioWorld briefs for Sept. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Sept. 22, 2025.

The ‘molecular revolution’ driving R&D of new cancer therapeutics

BioWorld Asia

“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...

CHMP recommends EU approval of Bayer’s Lynkuet for hot flashes

BioWorld

Following the first approvals in the U.K., Canada, Australia and Switzerland, the EMA’s Committee for Medicinal Products for Human Use (CHMP) is now recommending...

Elderly woman holding illustration of brain with missing puzzle piece

Remynd’s REM-127 yields positive phase II data in Alzheimer’s

BioWorld

Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...